Dermira Commits $135M for Global Rights to Roche Eczema Drug

14:11 EDT 8 Aug 2017 | Xconomy

Skin treatments developer Dermira is adding another experimental drug to its pipeline that it plans to test as a potential treatment for eczema, through a deal announced this morning with healthcare giant Roche. But in picking up the global rights to lebrikizumab, Menlo Park, CA-based Dermira (NASDAQ: DERM) is entering a suddenly crowded field of […]

Original Article: Dermira Commits $135M for Global Rights to Roche Eczema Drug


More From BioPortfolio on "Dermira Commits $135M for Global Rights to Roche Eczema Drug"

Quick Search

Relevant Topics

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...